17,520 results match your criteria Breast Cancer and HER2


Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review.

Cancer Med 2019 Apr 19. Epub 2019 Apr 19.

Department of Surgery in Breast Cancer, Fudan University Shanghai Cancer Center, Shanghai, China.

Nearly 75% of breast cancers are hormone receptor-positive (HR+) and human epidermal growth factor receptor type 2-negative (HER2-), making endocrine therapy the mainstay of treatment for HR+ and HER2- combination. Although endocrine therapy, such as therapy with fulvestrant, is widely used in the clinic, endocrine resistance (primary or secondary) is inevitable and poses a serious clinical concern. However, the therapeutic landscape of HR+/HER2- breast cancer is rapidly changing and evolving. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2095DOI Listing

In silico markers: an evolutionary and statistical approach to select informative genes of human breast cancer subtypes.

Genes Genomics 2019 Apr 19. Epub 2019 Apr 19.

Department of Informatics, University of Evora, 7004-516, Evora, Portugal.

Background: Recent advancement in bioinformatics offers the ability to identify informative genes from high dimensional gene expression data. Selection of informative genes from these large datasets has emerged as an issue of major concern among researchers.

Objective: Gene functionality and regulatory mechanisms can be understood through the analysis of these gene expression data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13258-019-00816-8DOI Listing

Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).

Breast Cancer Res Treat 2019 Apr 19. Epub 2019 Apr 19.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Purpose: Women with HER2-positive breast cancer treated prior to effective anti-HER2 therapy have higher rates of local-regional recurrence (LRR) than those with HER2-negative disease. Effective systemic therapy, however, has been shown to decrease LRR. This study examines LRR in women with HER2-positive breast cancer treated on a single-arm prospective multicenter trial of adjuvant trastuzumab (H) and paclitaxel (T). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05238-4DOI Listing

Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarker.

Clin Exp Med 2019 Apr 20. Epub 2019 Apr 20.

Department of Laboratory Medicine, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530021, Guangxi, China.

Tetraspanins have been implicated in multiple biological functions including protein networking and cell signaling. NET-6 (TSPAN 13) has been demonstrated to be a tumor suppressor gene in breast cancer, while CD151 is more likely to act as an oncogene. However, the biological function of both proteins is still inconclusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10238-019-00554-xDOI Listing

Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy.

Postgrad Med J 2019 Apr 19. Epub 2019 Apr 19.

Department of Surgery, Queen Mary Hospital, Hong Kong, China

Background: Over the last 10 years, there has been a major treatment revolution for early human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We aimed to explore the outcome of different neoadjuvant chemotherapy in a tertiary breast cancer centre with early HER2-positive breast cancer as well as factors associated with pathological complete response (pCR) and recurrence-free survival (RFS). The pattern of recurrence was also studied. Read More

View Article

Download full-text PDF

Source
http://pmj.bmj.com/lookup/doi/10.1136/postgradmedj-2018-1357
Publisher Site
http://dx.doi.org/10.1136/postgradmedj-2018-135739DOI Listing
April 2019
1 Read

New Insights into the Implication of Epigenetic Alterations in the EMT of Triple Negative Breast Cancer.

Cancers (Basel) 2019 Apr 18;11(4). Epub 2019 Apr 18.

Laboratoire d'Oncologie Moléculaire, Centre Jean PERRIN et IMoST, UMR 1240, Inserm/Université Clermont Auvergne 58 rue Montalembert, 63000 Clermont-Ferrand, France.

Breast cancer is the most common cancer and leading cause of cancer death among women worldwide, encompassing a wide heterogeneity of subtypes with different clinical features. During the last two decades, the use of targeted therapies has emerged in clinical research in order to increase treatment efficiency, improve prognosis and reduce recurrence. However, the triple negative breast cancer (TNBC) subtype remains a clinical challenge, with poor prognosis since no therapeutic targets have been identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11040559DOI Listing

Trastuzumab-Modified Gold Nanoparticles Labeled with At as a Prospective Tool for Local Treatment of HER2-Positive Breast Cancer.

Nanomaterials (Basel) 2019 Apr 18;9(4). Epub 2019 Apr 18.

Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.

Highly localized radiotherapy with radionuclides is a commonly used treatment modality for patients with unresectable solid tumors. Herein, we propose a novel α-nanobrachytherapy approach for selective therapy of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This uses local intratumoral injection of 5-nm-diameter gold nanoparticles (AuNPs) labeled with an α-emitter (At), modified with polyethylene glycol (PEG) chains and attached to HER2-specific monoclonal antibody (trastuzumab). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/nano9040632DOI Listing

Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer.

JAMA Netw Open 2019 Apr 5;2(4):e192561. Epub 2019 Apr 5.

Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio.

Importance: There has been significant recent interest in understanding the utility of quantitative imaging to delineate breast cancer intrinsic biological factors and therapeutic response. No clinically accepted biomarkers are as yet available for estimation of response to human epidermal growth factor receptor 2 (currently known as ERBB2, but referred to as HER2 in this study)-targeted therapy in breast cancer.

Objective: To determine whether imaging signatures on clinical breast magnetic resonance imaging (MRI) could noninvasively characterize HER2-positive tumor biological factors and estimate response to HER2-targeted neoadjuvant therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamanetworkopen.2019.2561DOI Listing

Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers.

Eur J Breast Health 2019 Apr 1;15(2):125-129. Epub 2019 Apr 1.

Department of Pathology and Surgery, Tepecik Training and Research Hospital, İzmir, Turkey.

Objective: Breast cancer is the most common cancer among women worldwide. Adenine thymine-rich interactive domain 1A (ARIDIA) is a tumor suppressor gene involved in chromatin remodeling and it encodes the ARIDIA protein. Recent studies have shown the loss of ARIDIA protein expression in different carcinomas may have a prognostic significance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5152/ejbh.2019.4677DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456276PMC

MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer.

J Control Release 2019 Apr 15. Epub 2019 Apr 15.

Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:

Liposomal peptide-based vaccines can potentially suppress cancer cells proliferation in the host. To enhance the effectiveness of vaccination against cancer, additional strategies should also be employed. One strategy to promote peptide-based vaccine efficacy and induce powerful immune responses, is simultaneous activation of CD4 and CD8 T cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.04.019DOI Listing
April 2019
1 Read

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial.

JAMA Oncol 2019 Apr 18:e190339. Epub 2019 Apr 18.

Department of Gynecology and Obstetrics, Hospital Pérola Byington, São Paulo, Brazil.

Importance: Confirmation of long-term comparability between subcutaneous and intravenous trastuzumab is essential.

Objective: To evaluate efficacy and safety of subcutaneous trastuzumab compared with that of intravenous trastuzumab for patients with ERBB2 (HER2)-positive early breast cancer after 6 years' follow-up in the HannaH (Enhanced Treatment With Neoadjuvant Herceptin) trial.

Design, Setting, And Participants: Open-label, prospective, multicenter, international, neoadjuvant-adjuvant, randomized, phase 3 noninferiority clinical trial (primary end points: pathologic complete response and serum trough concentration predose cycle 8) conducted for 596 patients with ERBB2-positive early breast cancer enrolled from October 19, 2009, to December 1, 2010. Read More

View Article

Download full-text PDF

Source
http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamaoncol.2019.0339DOI Listing
April 2019
1 Read

Differential expression of senescence tumour markers and its implications on survival outcomes of breast cancer patients.

PLoS One 2019 18;14(4):e0214604. Epub 2019 Apr 18.

Ingham Institute for Applied Medical Research, Liverpool, NSW Australia.

Breast cancer is a heterogeneous disease displaying different histopathological characteristics, molecular profiling and clinical behavior. This study describes the expression patterns of senescence markers P53, DEC1 and DCR2 and assesses their significance on patient survival as a single or combined marker with P16 or P14 using breast cancer progression series. One thousand and eighty (1080) patients with primary invasive ductal carcinoma, no special type, were recruited through an 11-year retrospective study period. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0214604PLOS
April 2019
1 Read

DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity.

JCI Insight 2019 Apr 18;4(8). Epub 2019 Apr 18.

Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, USA.

Specific antibody therapy, including mAbs and bispecific T cell engagers (BiTEs), are important new tools for cancer immunotherapy. However, these approaches are slow to develop and may be limited in their production, thus restricting the patients who can access these treatments. BiTEs exhibit a particularly short half-life and difficult production. Read More

View Article

Download full-text PDF

Source
https://insight.jci.org/articles/view/126086
Publisher Site
http://dx.doi.org/10.1172/jci.insight.126086DOI Listing
April 2019
1 Read

Cytotoxic effect of aqueous ethanolic extract of Luffa cylindrica leaves on cancer stem cells CD44/24 in breast cancer patients with various molecular sub-types using tissue samples in vitro.

J Ethnopharmacol 2019 Apr 14;238:111877. Epub 2019 Apr 14.

Medical Research Department, National Institute of Occupational Safety and Health, Egypt. Electronic address:

Ethnopharmacological Relevance: Luffa cylindrica (L.) M.Roem is a climbing plant its parts have been used as traditional medicine for the treatment of different types of diseases including diarrhea, inflammation, cancer and viral infections. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03788741193063
Publisher Site
http://dx.doi.org/10.1016/j.jep.2019.111877DOI Listing
April 2019
5 Reads

Heterologous Prime-Boost Enhances the Antitumor Immune Response Elicited by Plant-Virus-Based Cancer Vaccine.

J Am Chem Soc 2019 Apr 16. Epub 2019 Apr 16.

Department of Biomedical Engineering , Case Western Reserve University , 10900 Euclid Avenue , Cleveland , Ohio 44106 , United States.

New cancer vaccine strategies are required to vanquish the self-tolerance and elicit robust immune responses against tumor-associated antigens and/or neoantigens. Contemporary approaches in nanomedicine center on the use of a single nanocarrier modified with multiple copies of multiple different functional domains, e.g. Read More

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/jacs.9b01523
Publisher Site
http://dx.doi.org/10.1021/jacs.9b01523DOI Listing
April 2019
2 Reads

Significance of MMP-9 and VEGF-C expression in North Indian women with breast cancer diagnosis.

Mol Cell Biochem 2019 Apr 16. Epub 2019 Apr 16.

Environmental Biochemistry and Molecular Biology Laboratory, Department of Biochemistry, University College of Medical Sciences & G.T.B. Hospital (University of Delhi), Dilshad Garden, Delhi, 110095, India.

Metastasis accounts for the majority of cancer-associated mortality and renders the targeted therapy fruitless in the patients of breast cancer. Matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF-C) are thought to be involved in tumor progression and metastasis. The aim of this study was to investigate the expression of MMP-9 and VEGF-C at both mRNA and protein levels in breast cancer and to correlate with lymph node metastasis and other clinicopathological characteristics. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11010-019-03515-w
Publisher Site
http://dx.doi.org/10.1007/s11010-019-03515-wDOI Listing
April 2019
1 Read

ER+/HER2+ breast cancer: are we really de-escalating?

Ann Oncol 2019 Apr 16. Epub 2019 Apr 16.

Medicine, Institut Jules Bordet and L'Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz130DOI Listing
April 2019
1 Read

Positive or close margins: reoperation rate and second conservative resection or total mastectomy?

Cancer Manag Res 2019 28;11:2507-2516. Epub 2019 Mar 28.

Department of Surgical Oncology, Paoli Calmettes Institute, 13009 Marseille, France.

Introduction: Reoperation after breast-conserving surgery (BCS) could be proposed for positive or close margins. Reoperation type, re-excision or mastectomy, depends on several factors in relation to patient's and tumor's characteristics. We have analyzed our breast cancer (BC) database in order to determine second and third attempts for BCS and mastectomy rates, as well as associated factors for type of surgery. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/positive-or-close-margins-reoperat
Publisher Site
http://dx.doi.org/10.2147/CMAR.S190852DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445211PMC
March 2019
2 Reads

Hormone Receptors and Human Epidermal Growth Factor (HER2) Expression in Fine-Needle Aspirates from Metastatic Breast Carcinoma - Role in Patient Management.

J Cytol 2019 Apr-Jun;36(2):94-100

Department of Pathology, Faculty of Medicine, Kuwait University, Kuwait.

Introduction: Estrogen receptors (ER), progesterone receptors (PR), and epidermal growth factor (HER2) are prognostic and predictive factors for breast carcinoma. We determined them by immunohistochemistry (IHC) on cell blocks from fine-needle aspirates (FNA) of metastatic breast carcinoma to axillary lymphnodes and compared them with that reported in the primary breast carcinoma (PBC) to document any change in their expression for future management.

Materials And Methods: ER, PR, and HER2 by IHC and HER2 oncogene by fluorescent in-situ hybridization (FISH) were studied on cell blocks of FNA of axillary lymphnodes in 53 of 94 PBC cases from 2012 to 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/JOC.JOC_117_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425780PMC
April 2019
1 Read

Clinical and Cyto-Morphological Characterization of Triple Negative Breast Cancer.

J Cytol 2019 Apr-Jun;36(2):84-88

Department of Surgery, GSVM Medical College, Kanpur, Uttar Pradesh, India.

Objective: Triple negative breast cancer (TNBC), despite being the uncommon subtype, contributes a major portion to mortality and associated with poor prognosis. The purpose of this study was to evaluate the cytological criteria for the diagnosis of TNBC through fine-needle aspiration cytology (FNAC).

Material And Method: Clinical, cytological, histological, and immunohistochemical (IHC) data of 256 patients were evaluated, and patient were classified as TNBC and non-TNBC phenotype by IHC. Read More

View Article

Download full-text PDF

Source
http://www.jcytol.org/text.asp?2019/36/2/84/251101
Publisher Site
http://dx.doi.org/10.4103/JOC.JOC_47_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425775PMC
April 2019
2 Reads

A Case of Locally Advanced Breast Cancer in a 59-Year-Old Man Requiring a Modified Approach to Management.

Am J Case Rep 2019 Apr 17;20:531-536. Epub 2019 Apr 17.

Department of General Surgery, Surgical Oncology Unit, King Fahad Specialist Hospital, Dammam, Saudi Arabia.

BACKGROUND Male breast cancer is rare, accounting for approximately 1% of all malignancies in men. The lack of awareness of this rare cancer results in delayed diagnosis and its aggressive behavior can result in poor prognosis. This report is of a case of locally advanced, high-grade breast cancer in a 59-year-old man who was reluctant to undergo diagnostic procedures, and describes the approach to clinical management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.915377DOI Listing

An oligonucleotide probe incorporating the chromophore of green fluorescent protein is useful for the detection of HER-2 mRNA breast cancer marker.

Eur J Med Chem 2019 Apr 9;173:99-106. Epub 2019 Apr 9.

Department of Chemistry, Bar-Ilan University, Ramat-Gan, 52900, Israel. Electronic address:

Diagnosis and treatment of breast cancer can be greatly enhanced and personalized based on the quantitative detection of mRNA markers. Here, we targeted the development of a fluorescent oligonucleotide probe to detect specifically the HER-2 mRNA breast cancer marker. We have selected the chromophore of the Green Fluorescent Protein (GFP), 4-hydroxybenzylidene imidazolinone (HBI), as a fluorophore covalently bound to an oligonucleotide probe and potentially capable of intercalating within a probe-mRNA duplex. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2019.04.013DOI Listing
April 2019
2 Reads

CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors.

Elife 2019 Apr 16;8. Epub 2019 Apr 16.

Department of Pharmacology and Cancer Biology, Duke University, Durham, United States.

Over half of breast cancer related deaths are due to recurrence five or more years after initial diagnosis and treatment. This latency suggests that a population of residual tumor cells can survive treatment and persist in a dormant state for many years. The role of the microenvironment in regulating the survival and proliferation of residual cells following therapy remains unexplored. Read More

View Article

Download full-text PDF

Source
https://elifesciences.org/articles/43653
Publisher Site
http://dx.doi.org/10.7554/eLife.43653DOI Listing
April 2019
4 Reads

Neoadjuvant Chemotherapy in Non-Metastatic Breast Cancer- A Study on Practice Trends in a Regional Cancer Treatment Service.

Intern Med J 2019 Apr 16. Epub 2019 Apr 16.

Medical Oncology, Palmerston North Hospital, New Zealand.

Aims: Neoadjuvant Chemotherapy (NACT) is increasingly used for managing locally advanced and high risk non-metastatic breast cancer(NMBC). The goal of this study is to describe trends in NACT use, assess compliance to best practice recommendations and determine treatment response rates in a regional cancer treatment service.

Method: In this retrospective cross- sectional study, electronic records of patients who underwent NACT in centres covered by the Midcentral Regional Cancer Treatment Service (RCTS) in 2013 and 2017 were reviewed. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/imj.14326
Publisher Site
http://dx.doi.org/10.1111/imj.14326DOI Listing
April 2019
1 Read

Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer.

Horm Cancer 2019 Apr 15. Epub 2019 Apr 15.

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., M4-C308, Seattle, WA, 98109, USA.

Oral contraceptive use is a well-established risk factor for breast cancer and is common among reproductive-aged women in the USA. Its relationship with less common, more aggressive, molecular subtypes is less clear. A population-based case-case analysis was conducted comparing three less common molecular subtypes to luminal A breast cancer among 1701 premenopausal cases aged 21-49 diagnosed with a first primary invasive breast cancer between 2004 and 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12672-019-00362-5DOI Listing
April 2019
1 Read

Phase I study of intermittent high dose lapatinib alternating with capecitabine for HER2-positive breast cancer patients with central nervous system metastases.

Clin Cancer Res 2019 Apr 15. Epub 2019 Apr 15.

Medicine, Memorial Sloan Kettering Cancer Center

Purpose: Lapatinib and capecitabine cross the blood tumor-barrier in breast cancer brain metastasis but have modest clinical efficacy. Administration of high dose tyrosine kinase inhibitor (TKI) has been evaluated in brain metastases and primary brain tumors as a strategy to improve drug exposure in the central nervous system (CNS).We derived a rational drug scheduling of intermittent high dose lapatinib alternating with capecitabine-basedon our preclinical data and Norton-Simon mathematical modeling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3502DOI Listing

Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy.

Biomed J 2019 Feb 28;42(1):66-74. Epub 2019 Mar 28.

Department of General Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. Electronic address:

Background: Neoadjuvant chemotherapy (NAC) is the standard approach for downstaging of locally advanced breast cancer and can improve breast conservation rates. A pathological complete response (pCR) after NAC associated with favorable long-term outcomes has been described. There is still a high locoregional recurrence (LRR) rate after NAC and the influence of age on LRR after NAC is unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bj.2018.10.007DOI Listing
February 2019
1 Read

Development and characterisation of acquired radioresistant breast cancer cell lines.

Radiat Oncol 2019 Apr 15;14(1):64. Epub 2019 Apr 15.

The Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Edinburgh, Scotland.

Background: Radiotherapy plays an important role in the multimodal treatment of breast cancer. The response of a breast tumour to radiation depends not only on its innate radiosensitivity but also on tumour repopulation by cells that have developed radioresistance. Development of effective cancer treatments will require further molecular dissection of the processes that contribute to resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13014-019-1268-2DOI Listing
April 2019
1 Read

Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation.

J Exp Clin Cancer Res 2019 Apr 12;38(1):160. Epub 2019 Apr 12.

Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Via Luciano Armanni, 5, 80138 Napoli, Naples, Italy.

Background: Glucose-6-phospate dehydrogenase (G6PD) is the limiting enzyme of the pentose phosphate pathway (PPP) correlated to cancer progression and drug resistance. We previously showed that G6PD inhibition leads to Endoplasmic Reticulum (ER) stress often associated to autophagy deregulation. The latter can be induced by target-based agents such as Lapatinib, an anti-HER2 tyrosine kinase inhibitor (TKI) largely used in breast cancer treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1164-5DOI Listing
April 2019
1 Read

Glucocorticoid-dependent expression of IAP participates in the protection against TNF-mediated cytotoxicity in MCF7 cells.

BMC Cancer 2019 Apr 15;19(1):356. Epub 2019 Apr 15.

Departamento de Medicina Genomica y Toxicologia Ambiental, Instituto de Investigaciones Biomedicas (IIBO), Universidad Nacional Autonoma de Mexico (UNAM), 04510 Ciudad de Mexico (CDMX), Mexico, Mexico.

Background: Glucocorticoid receptor (GR) activation has been associated with breast cancer cell survival in vitro. Glucocorticoid (GC)-dependent protection against tumor necrosis factor (TNF)-induced cell death has been well characterized in MCF7 luminal A breast cancer cells. The GR activates a variety of protective mechanisms, such as inhibitors of apoptosis proteins (IAPs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5563-yDOI Listing
April 2019
1 Read

The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast.

Am J Clin Pathol 2019 Apr 15. Epub 2019 Apr 15.

Breast Pathology Section, Department of Pathology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL.

Objectives: The aims were to evaluate the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis in ductal carcinoma in situ (DCIS) of the breast.

Methods: We reviewed 85 pure DCIS cases treated with surgical excision at our institution, including 51 luminal A (estrogen receptor [ER] positive/human epidermal growth factor 2 [HER2] negative), 15 luminal B (ER+/HER2+), 13 HER2 (ER-/HER2+), and six basal-like (ER-/HER2-/CK5/6+). The extent and intensity of PD-1 and PD-L1 immunohistochemical staining in the tumor-infiltrating lymphocytes (TILs) and in the tumor cells were recorded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajcp/aqz020DOI Listing
April 2019
1 Read

The Allele of rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin.

Front Oncol 2019 28;9:193. Epub 2019 Mar 28.

Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain.

The minor allele () of the single-nucleotide polymorphism (SNP) , located near the () gene, has been associated with an increased likelihood of treatment success with metformin in type 2 diabetes. We herein investigated whether the same SNP would predict clinical response to neoadjuvant metformin in women with early breast cancer (BC). DNA was collected from 79 patients included in the intention-to-treat population of the METTEN study, a phase 2 clinical trial of HER2-positive BC patients randomized to receive either metformin combined with anthracycline/taxane-based chemotherapy and trastuzumab or equivalent regimen without metformin, before surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00193DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447648PMC
March 2019
1 Read

Shed HER2 surrogacy evaluation in primary breast cancer patients: a study assessing tumor tissue HER2 expression at both extracellular and intracellular levels.

Scand J Clin Lab Invest 2019 Apr 15:1-8. Epub 2019 Apr 15.

a Regional Center for Biomarkers, Department of Clinical Pathology and Transfusion Medicine , Azienda ULSS 3 Serenissima, Regional Hospital , Venice , Italy.

The aim of the present study was to investigate serum HER2 extracellular domain (ECD) as a putative surrogate marker of the shedding phenomenon of HER2 receptor from the tumor tissue of primary breast cancer (BC) patients. A pilot retrospective study was conducted on 100 matched serum and tissue samples from patients with node-positive primary BC, stage II/III. Analysis of association and concordance between serum HER2 ECD levels (measured by chemiluminescence immunoassay) and the expression in matched tumor tissue of HER2 ECD and intracellular receptor domain (ICD) (determined by immunohistochemistry) were performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00365513.2019.1600200DOI Listing
April 2019
2 Reads

Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases.

Breast Cancer Res Treat 2019 Apr 13. Epub 2019 Apr 13.

Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.

Purpose: Brain metastases from breast cancer are frequently managed with brain-directed radiation but the impact of subtype on intracranial recurrence patterns after radiation has not been well-described. We investigated intracranial recurrence patterns of brain metastases from breast cancer after brain-directed radiation to facilitate subtype-specific management paradigms.

Methods: We retrospectively analyzed 349 patients with newly diagnosed brain metastases from breast cancer treated with brain-directed radiation at Brigham and Women's Hospital/Dana-Farber Cancer Institute between 2000 and 2015. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05236-6
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05236-6DOI Listing
April 2019
3 Reads

Computational algorithms for in silico profiling of activating mutations in cancer.

Cell Mol Life Sci 2019 Apr 13. Epub 2019 Apr 13.

Graduate Group in Biochemistry and Molecular Biophysics, University of Pennsylvania, Philadelphia, PA, USA.

Methods to catalog and computationally assess the mutational landscape of proteins in human cancers are desirable. One approach is to adapt evolutionary or data-driven methods developed for predicting whether a single-nucleotide polymorphism (SNP) is deleterious to protein structure and function. In cases where understanding the mechanism of protein activation and regulation is desired, an alternative approach is to employ structure-based computational approaches to predict the effects of point mutations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00018-019-03097-2DOI Listing
April 2019
1 Read

Antibody Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.

Clin Cancer Res 2019 Apr 12. Epub 2019 Apr 12.

Gustave Roussy Cancer Campus.

Since the first approval of gemtuzumab ozogamicin (Mylotarg; CD33 targeted), 2 additional antibody drug conjugates (ADCs)-brentuximab vedotin (Adcetris; CD30 targeted) and inotuzumab ozogamicin (Besponsa; CD22 targeted)-have been approved for hematologic cancers and 1 ADC, trastuzumab emtansine (Kadcyla; HER2 targeted), has been approved to treat breast cancer. Despite a clear clinical benefit being demonstrated for all 4 approved ADCs, the toxicity profiles are comparable to those of standard-of-care chemotherapeutics, with dose-limiting toxicities associated with the mechanism of activity of the cytotoxic warhead. However, the enthusiasm to develop ADCs has not been dampened; approximately 80 ADCs are in clinical development in nearly 600 clinical trials, and 2 to 3 novel ADCs are likely to be approved within the next few years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-0272DOI Listing
April 2019
1 Read

Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).

Breast Cancer Res Treat 2019 Apr 11. Epub 2019 Apr 11.

Division of Cancer Medicine, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Purpose: Lapatinib (L) is approved in combination with capecitabine or letrozole for patients with trastuzumab-resistant HER2-positive metastatic breast cancer (MBC). However, there is no efficacy data of L in patients who received prior pertuzumab (P) and ado-trastuzumab emtansine (T-DM1), now included as standard first- and second-line therapies, respectively. The goal of this study was to assess the efficacy of L in a contemporary patient population that received prior P and/or T-DM1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05081-zDOI Listing
April 2019
1 Read

Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer.

Ann Surg Oncol 2019 Apr 11. Epub 2019 Apr 11.

Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.

Purpose: Mucinous carcinoma (MC) is a rare breast cancer with favorable outcome. Unlike typical breast cancer, the current guidelines do not recommend chemotherapy or anti-human epidermal growth factor receptor 2 (HER2) therapy for hormone receptor (HR)-positive MC, regardless of HER2 status. We evaluated the prognostic implication of HER2 status in HR-positive MC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-019-07332-9DOI Listing
April 2019
1 Read

Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.

Cancer Chemother Pharmacol 2019 Apr 11. Epub 2019 Apr 11.

Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA.

Purpose: To characterize the pharmacokinetics (PK) of, and perform an exploratory exposure-response (E-R) analysis for, pertuzumab in patients with HER2-positive early breast cancer (EBC) within the APHINITY study (NCT01358877, BIG 4-11/BO25126/TOC4939G).

Methods: A previously developed pertuzumab two-compartment linear population pharmacokinetic (popPK) model was subjected to external validation to examine appropriateness for describing pertuzumab concentrations from the APHINITY study. Pharmacokinetic drug-drug interactions (DDIs) between pertuzumab, trastuzumab, and chemotherapy were assessed by comparing observed serum or plasma C, C, and AUC geometric mean ratios with 90% CIs. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-019-03826-1
Publisher Site
http://dx.doi.org/10.1007/s00280-019-03826-1DOI Listing
April 2019
3 Reads

Predictive and prognostic value of ZEB1 protein expression in breast cancer patients with neoadjuvant chemotherapy.

Cancer Cell Int 2019 29;19:78. Epub 2019 Mar 29.

Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 160 Pujian Road, Pudong New District, Shanghai, 200127 People's Republic of China.

Background: Zinc finger E-box binding homeobox 1 (ZEB1) is a molecule involved in the progression of epithelial-to-mesenchymal transition (EMT) in various kinds of cancers. Here, we aimed to determine whether the expression of the ZEB1 protein is related to the response of patients to neoadjuvant therapy as well as their survival outcome.

Methods: Immunohistochemistry (IHC) was performed on paraffin-embedded tumor samples from core needle biopsy before neoadjuvant therapy (NAT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-019-0793-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441148PMC
March 2019
1.989 Impact Factor

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.

Mod Pathol 2019 Apr 11. Epub 2019 Apr 11.

Cancer Research UK (CRUK) Cambridge Institute, University of Cambridge, Cambridge, UK.

Although most women with luminal breast cancer do well on endocrine therapy alone, some will develop fatal recurrence thereby necessitating the need to prospectively determine those for whom additional cytotoxic therapy will be beneficial. Categorical combinations of immunohistochemical measures of ER, PR, HER2, and KI67 are traditionally used to classify patients into luminal A-like and B-like subtypes for chemotherapeutic reasons, but this may lead to the loss of prognostically relevant information. Here, we compared the prognostic value of quantitative measures of these markers, combined in the IHC4-score, to categorical combinations in subtypes. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41379-019-0270-4
Publisher Site
http://dx.doi.org/10.1038/s41379-019-0270-4DOI Listing
April 2019
4 Reads

The Loss of Lymph Node Metastases After Neoadjuvant Chemotherapy in Patients With Cytology-proven Axillary Node-positive Primary Breast Cancer.

Clin Breast Cancer 2019 Mar 11. Epub 2019 Mar 11.

Department of Breast Surgical Oncology, St Luke's International Hospital, Tokyo, Japan; Department of Breast Surgical Oncology, Watanabe Hospital, Tokyo, Japan. Electronic address:

Background: Axillary lymph node (LN) dissection after neoadjuvant chemotherapy (NAC) still remains a standard treatment of initially LN-positive primary breast cancer because of the difficulty of assessment of LN status. The aim of this study was to assess the LN status after NAC in initially LN-positive primary breast cancer patients who were assessed as clinically LN-negative after NAC (ycN0) and identify factors associated with loss of LN metastasis.

Patients And Methods: The study cohort comprised 279 patients with cytology-proven LN-positivity before NAC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.03.001DOI Listing
March 2019
1 Read

Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.

Value Health 2019 Apr 11;22(4):408-415. Epub 2019 Mar 11.

Genentech, Inc., South San Francisco, USA.

Objective: The APHINITY trial assessed the effectiveness and the safety of adding pertuzumab to trastuzumab and chemotherapy (THP) compared to trastuzumab and chemotherapy (TH) in the adjuvant management of human epidermal growth factor 2-positive (HER2+) breast cancer. We performed a study to project the potential cost-effectiveness of THP vs. TH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jval.2018.11.014DOI Listing
April 2019
2 Reads

Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.

J Transl Med 2019 Apr 11;17(1):123. Epub 2019 Apr 11.

Laboratory of Molecular Immuno‑Oncology, Faculty of Medicine of Monastir, Monastir University, 5019, Monastir, Tunisia.

Background: Triple negative breast cancer (TNBC) has been classified as a disease subgroup defined by the lack of expression of estrogen and progesterone receptors as well as the absence of the human epidermal growth factor receptor-2 (HER2) overexpression. Germline mutations in the BRCA1 gene have been associated with TNBC. Approximately 70% of breast cancers arising in BRCA1 mutation carriers and up to 23% of breast cancers in BRCA2 carriers display a triple negative phenotype. Read More

View Article

Download full-text PDF

Source
https://translational-medicine.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s12967-019-1873-8DOI Listing
April 2019
4 Reads

Integrative Analysis Reveals Subtype-Specific Regulatory Determinants in Triple Negative Breast Cancer.

Cancers (Basel) 2019 Apr 10;11(4). Epub 2019 Apr 10.

College of Pharmacy, University of Manitoba, Winnipeg, MB R3E 0T5, Canada.

Different breast cancer (BC) subtypes have unique gene expression patterns, but their regulatory mechanisms have yet to be fully elucidated. We hypothesized that the top upregulated (Yin) and downregulated (Yang) genes determine the fate of cancer cells. To reveal the regulatory determinants of these Yin and Yang genes in different BC subtypes, we developed a lasso regression model integrating DNA methylation (DM), copy number variation (CNV) and microRNA (miRNA) expression of 391 BC patients, coupled with miRNA-target interactions and transcription factor (TF) binding sites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11040507DOI Listing
April 2019
1 Read

Preparation of Lu-Trastuzumab injection for treatment of breast cancer.

Appl Radiat Isot 2019 Apr 3;148:184-190. Epub 2019 Apr 3.

Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, 400085, India; Homi Bhabha National Institute, Anushakti Nagar, Mumbai, 400 094, India.

The objective of this study was the facile preparation of Lu-CHX-A''-DTPA-Trastuzumab injection for breast cancer therapy. Trastuzumab conjugated with CHX-A''-DTPA-NCS was radiolabeled with Lu in >95% radiochemical purity. In vitro studies in SKBR3 and MDA-MB-453 cells confirmed specificity of Lu-CHX-A''-DTPA-Trastuzumab to HER2 positive cells. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09698043183084
Publisher Site
http://dx.doi.org/10.1016/j.apradiso.2019.04.002DOI Listing
April 2019
2 Reads
1.056 Impact Factor

Quantitative Dot Blot (QDB) as a universal platform for absolute quantification of tissue biomarkers.

Anal Biochem 2019 Apr 8;576:42-47. Epub 2019 Apr 8.

Yantai Quanticision Diagnostics Inc., A Division of Quanticision Diagnostics, Inc. (US), Yantai Hi-tech District, Shandong, 264670, PR China; Medicine and Pharmarcy Research Center, Precision Medicine Division, Binzhou Medical University, Laishan District, Shandong, 264003, PR China. Electronic address:

To circumvent the limitations associated with sandwich ELISA for tissue biomarker quantitation, Quantitative Dot Blot method (QDB) was proposed using antibodies clinically validated for immunohistochemistry (IHC), as this method requires only one primary antibody in the analysis. The protein levels of four breast cancer tissue biomarkers, including Estrogen Receptor (ER), Progesterone Receptor (PR), Ki67 and Her2, were absolutely quantitated successfully in 190 frozen breast tissue biopsies, and the results were further verified with provided IHC results. We propose QDB method as an alternative platform to Sandwich ELISA for absolute quantitation of tissue biomarkers with significantly reduced developing effort and time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ab.2019.04.003DOI Listing
April 2019
1 Read
2.219 Impact Factor

Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer.

Breast Cancer Res Treat 2019 Apr 10. Epub 2019 Apr 10.

Department of Surgical Oncology, Radboud University Medical Center Nijmegen, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands.

Purpose: To analyze the influence of hormone receptors (HR) and Human Epidermal growth factor Receptor-2 (HER2)-based molecular subtypes in stage III inflammatory breast cancer (IBC) on tumor characteristics, treatment, pathologic response to neoadjuvant chemotherapy (NACT), and overall survival (OS).

Methods: Patients with stage III IBC, diagnosed in the Netherlands between 2006 and 2015, were classified into four breast cancer subtypes: HR+/HER2- , HR+/HER2+ , HR-/HER2+ , and HR-/HER2- . Patient-, tumor- and treatment-related characteristics were compared. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05219-7
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05219-7DOI Listing
April 2019
4 Reads

Immunophenotyping of male breast cancer - Experience at a tertiary care centre.

Indian J Pathol Microbiol 2019 Apr-Jun;62(2):226-231

Department of Pathology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India.

Background: Male breast cancers (MBCs) are uncommon and account for 1% of all breast cancers. Medical conditions that increase the estrogen to testosterone ratio are implicated as the risk factors. Morphologically similar, but MBCs have biological differences compared with female breast cancer (FBC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/IJPM.IJPM_543_18DOI Listing
April 2019
1 Read

Cancer registries - guardians of breast cancer biomarker information: A systematic review.

Int J Biol Markers 2019 Apr 10:1724600819836097. Epub 2019 Apr 10.

European Commission, Joint Research Centre (JRC), Ispra, Italy.

Background: Breast cancer is the most common cancer and the leading cause of cancer-related death in females, with a large societal and economic impact. Decisions regarding its treatment are largely affected by the categorization into different subtypes with hormone receptor status and HER2 status being the most important predictive factors. Other biological markers play an important role for prognostic and predictive reasons. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1724600819836097DOI Listing
April 2019
1 Read